{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:11:56Z","timestamp":1772820716114,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"DOI":"10.7759\/cureus.104765","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:05:34Z","timestamp":1772798734000},"source":"Crossref","is-referenced-by-count":0,"title":["Oncological Safety of Testosterone Replacement Therapy in Men With a History of Prostate Cancer: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Vit\u00f3rio  A","family":"Alexandre Alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 A","family":"Brasileiro Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernani L","family":"Falcao Bisneto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiago F","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gleydson S","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Guilherme P","family":"Santos De Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr\u00f4nio Eduardo A","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Porf\u00edrio F","family":"Medeiros J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)64820-3","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"46","author":"Huggins C","year":"1941","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 1941, 46:997-1007. 10.1016\/s0022-5347(05)64820-3","journal-title":"J Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13417","article-title":"Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis","volume":"118","author":"Boyle P","year":"2016","unstructured":"Boyle P, Koechlin A, Bota M, et al.. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016, 118:731-41. 10.1111\/bju.13417","journal-title":"BJU Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler A","year":"2009","unstructured":"Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009, 55:310-20. 10.1016\/j.eururo.2008.09.024","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2018.07.064","article-title":"Testosterone therapy for high-risk prostate cancer survivors: a systematic review and meta-analysis","volume":"126","author":"Teeling F","year":"2019","unstructured":"Teeling F, Raison N, Shabbir M, et al.. Testosterone therapy for high-risk prostate cancer survivors: a systematic review and meta-analysis. Urology. 2019, 126:16-23. 10.1016\/j.urology.2018.07.064","journal-title":"Urology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020191","article-title":"Regulating androgen receptor function in prostate cancer: exploring the diversity of post-translational modifications","volume":"13","author":"Lumahan LE","year":"2024","unstructured":"Lumahan LE, Arif M, Whitener AE, Yi P. Regulating androgen receptor function in prostate cancer: exploring the diversity of post-translational modifications. Cells. 2024, 13:10.3390\/cells13020191","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson PA","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015, 15:701-11. 10.1038\/nrc4016","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai C","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023, 41:4267-78. 10.1200\/JCO.23.00433","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030663","article-title":"Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer","volume":"16","author":"Chen QH","year":"2024","unstructured":"Chen QH, Munoz E, Ashong D. Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer. Cancers (Basel). 2024, 16:10.3390\/cancers16030663","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen PL","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, et al.. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015, 67:825-36. 10.1016\/j.eururo.2014.07.010","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin S","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR, et al.. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018, 103:1715-44. 10.1210\/jc.2018-00229","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.11.013","article-title":"Obesity and prostate cancer: weighing the evidence","volume":"63","author":"Allott EH","year":"2013","unstructured":"Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013, 63:800-9. 10.1016\/j.eururo.2012.11.013","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder PJ","year":"2016","unstructured":"Snyder PJ, Bhasin S, Cunningham GR, et al.. Effects of testosterone treatment in older men. N Engl J Med. 2016, 374:611-24. 10.1056\/NEJMoa1506119","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21196","article-title":"Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen\/ablation in men with castration resistant prostate cancer","volume":"70","author":"Denmeade SR","year":"2010","unstructured":"Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen\/ablation in men with castration resistant prostate cancer. Prostate. 2010, 70:1600-7. 10.1002\/pros.21196","journal-title":"Prostate"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall JP","year":"2018","unstructured":"Mulhall JP, Trost LW, Brannigan RE, et al.. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018, 200:423-32. 10.1016\/j.juro.2018.03.115","journal-title":"J Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.04.010","article-title":"European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease","volume":"88","author":"Salonia A","year":"2025","unstructured":"Salonia A, Capogrosso P, Boeri L, et al.. European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease. Eur Urol. 2025, 88:76-102. 10.1016\/j.eururo.2025.04.010","journal-title":"Eur Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.672","article-title":"How to read a paper: papers that summarise other papers (systematic reviews and meta-analyses)","volume":"315","author":"Greenhalgh T","year":"1997","unstructured":"Greenhalgh T. How to read a paper: papers that summarise other papers (systematic reviews and meta-analyses). BMJ. 1997, 315:672-5. 10.1136\/bmj.315.7109.672","journal-title":"BMJ"},{"key":"ref18","unstructured":"Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2021). Accessed: March 6, 2026: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis JR","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977, 33:159-74.","journal-title":"Biometrics"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.01.005","article-title":"Oncologic outcomes of testosterone therapy for men on active surveillance for prostate cancer: a population-based analysis","volume":"60","author":"Kaplan-Marans E","year":"2024","unstructured":"Kaplan-Marans E, Zhang TR, Hu JC. Oncologic outcomes of testosterone therapy for men on active surveillance for prostate cancer: a population-based analysis. Eur Urol Open Sci. 2024, 60:36-43. 10.1016\/j.euros.2024.01.005","journal-title":"Eur Urol Open Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15042","article-title":"Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy","volume":"126","author":"Ahlering TE","year":"2020","unstructured":"Ahlering TE, My Huynh L, Towe M, et al.. Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy. BJU Int. 2020, 126:91-6. 10.1111\/bju.15042","journal-title":"BJU Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0241-3","article-title":"Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease","volume":"23","author":"Sarkar RR","year":"2020","unstructured":"Sarkar RR, Patel SH, Parsons JK, et al.. Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer Prostatic Dis. 2020, 23:689-95. 10.1038\/s41391-020-0241-3","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.5304","article-title":"Testosterone replacement therapy and risk of favorable and aggressive prostate cancer","volume":"35","author":"Loeb S","year":"2017","unstructured":"Loeb S, Folkvaljon Y, Damber JE, et al.. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017, 35:1430-6. 10.1200\/JCO.2016.69.5304","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682X.160270","article-title":"Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results","volume":"18","author":"Kacker R","year":"2016","unstructured":"Kacker R, Hult M, San Francisco IF, et al.. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016, 18:16-20. 10.4103\/1008-682X.160270","journal-title":"Asian J Androl"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.04.069","article-title":"Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes","volume":"196","author":"Ory J","year":"2016","unstructured":"Ory J, Flannigan R, Lundeen C, et al.. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016, 196:1082-9. 10.1016\/j.juro.2016.04.069","journal-title":"J Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.12.005","article-title":"Testosterone therapy in men with prostate cancer","volume":"69","author":"Kaplan AL","year":"2016","unstructured":"Kaplan AL, Hu JC, Morgentaler A, et al.. Testosterone therapy in men with prostate cancer. Eur Urol. 2016, 69:894-903. 10.1016\/j.eururo.2015.12.005","journal-title":"Eur Urol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.002","article-title":"Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy","volume":"190","author":"Pastuszak AW","year":"2013","unstructured":"Pastuszak AW, Pearlman AM, Lai WS, et al.. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013, 190:639-44. 10.1016\/j.juro.2013.02.002","journal-title":"J Urol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22438","article-title":"Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy","volume":"109","author":"Sarosdy MF","year":"2007","unstructured":"Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007, 109:536-41. 10.1002\/cncr.22438","journal-title":"Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/415768-oncological-safety-of-testosterone-replacement-therapy-in-men-with-a-history-of-prostate-cancer-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:05:36Z","timestamp":1772798736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/415768-oncological-safety-of-testosterone-replacement-therapy-in-men-with-a-history-of-prostate-cancer-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.104765","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}